COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AS A SECOND-LINE THERAPY IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA IN CHINA

被引：0
|
作者：
Xiao, D. [1 ]
Zhu, S. [1 ]
Sun, W. [2 ]
Xuan, J. [3 ]
机构：
[1] Shanghai Centennial Sci Co Ltd, Shanghai, Peoples R China
[2] Bayer Healthcare Co Ltd, Beijing, Peoples R China
[3] Sun Yat Sen Univ, Guangzhou, Guangdong, Peoples R China
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.831
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIH31
引用
收藏
页码：S187 / S188
页数：2
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of nivolumab in the second-line treatment for advanced esophageal squamous cell carcinoma
    Zhang, Peng-Fei
    Xie, Dan
    Li, Qiu
    FUTURE ONCOLOGY, 2020, 16 (17) : 1189 - 1198
  • [22] Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden
    Srivastava, Tushar
    Prabhu, Vimalanand S.
    Li, Haojie
    Xu, Ruifeng
    Zarabi, Natalie
    Zhong, Yichen
    Pellissier, James M.
    Perini, Rodolfo F.
    de Wit, Ronald
    Mamtani, Ronac
    EUROPEAN UROLOGY ONCOLOGY, 2020, 3 (05): : 663 - 670
  • [23] Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma
    Kudo, M.
    LIVER CANCER, 2016, 5 (04) : 235 - 244
  • [24] COST-EFFECTIVENESS OF SECOND-LINE VASOPRESSORS FOR THE TREATMENT OF SEPTIC SHOCK
    Lam, Simon
    Barreto, Erin
    Scott, Rachael
    Kashani, Kianoush
    Khanna, Ashish
    Bauer, Seth
    CRITICAL CARE MEDICINE, 2020, 48
  • [25] Cost-Effectiveness of Everolimus for Second-Line Treatment of Metastatic Renal Cell Carcinoma in Serbia
    Mihajlovic, Jovan
    Pechlivanoglou, Petros
    Sabo, Ana
    Tomic, Zdenko
    Postma, Maarten J.
    CLINICAL THERAPEUTICS, 2013, 35 (12) : 1909 - 1922
  • [26] Cost-effectiveness of second-line vasopressors for the treatment of septic shock
    Lam, Simon W.
    Barreto, Erin F.
    Scott, Rachael
    Kashani, Kianoush B.
    Khanna, Ashish K.
    Bauer, Seth R.
    JOURNAL OF CRITICAL CARE, 2020, 55 : 48 - 55
  • [27] COST-EFFECTIVENESS OF SUNITINIB AS SECOND-LINE TREATMENT FOR GASTROINTESTINAL STROMAL TUMOR(GIST) IN CHINA
    Ren, H.
    Zhang, J.
    Dong, P.
    VALUE IN HEALTH, 2015, 18 (07) : A455 - A455
  • [28] Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis
    Shlomai, Amir
    Leshno, Moshe
    Goldstein, Daniel A.
    PLOS ONE, 2018, 13 (11):
  • [29] COST-EFFECTIVENESS ANALYSIS OF CEMIPLIMAB AS SECOND-LINE THERAPY FOR RECURRENT CERVICAL CANCER IN JAPAN
    Maeda, Y. T. Shibata
    Chen, W.
    Morimoto, K.
    Moriwaki, K.
    Shimozuma, K.
    VALUE IN HEALTH, 2023, 26 (06) : S150 - S151
  • [30] COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS ACARBOSE AS SECOND-LINE THERAPY IN TYPE 2 DIABETES IN CHINA
    Gu, S.
    Shao, H.
    Zeng, Y.
    Shi, L.
    Dong, H.
    VALUE IN HEALTH, 2016, 19 (07) : A898 - A898
12345